Andrew Davies MRCP, PhD, University of Southampton, Southampton, UK outlines the utility of molecular profiling for the classification of diffuse large B-cell lymphoma (DLBCL) subtypes and subsequently, how this can be applied in treatment as therapeutic targeting of specific oncogenic abberations.This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).